GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Innate Pharma S.A.
Innate Pharma is a French biopharmaceutical company specializing in immuno-oncology. Its NASDAQ ADR price is dependent on clinical trial success and partnerships with major pharmaceutical companies, such as AstraZeneca, which help finance its expensive development efforts.
Share prices of companies in the market segment - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in the development of immunotherapeutic drugs that activate the innate immune system to fight cancer. We've classified it in the "Immuno-Oncology" segment. The chart below shows the dynamics of this cutting-edge sector.
Broad Market Index - GURU.Markets
Innate Pharma is a French biotech company specializing in the development of immunotherapeutic drugs that activate the innate immune system to fight cancer. It is a component of the GURU.Markets index. The chart below shows the US market. See how this company's stock compares to the US market trend.
Change in the price of a company, segment, and market as a whole per day
IPHA - Daily change in the company's share price Innate Pharma S.A.
For Innate Pharma, a biopharmaceutical company, change_co is a measure of innovation volatility. Daily fluctuations reflect news about clinical trials of its immuno-oncology platform. This metric forms the basis for biotech company analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Innate Pharma S.A. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with IPHA's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Innate Pharma is a French biotech company specializing in immuno-oncology. Its shares are driven by news of clinical trials and partnerships. The dynamics of such international players adds global context to the volatility of the US market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Innate Pharma S.A.
Innate Pharma S.A.'s year-over-year performance tells the story of its role in immuno-oncology. Its market capitalization growth over the past 12 months is driven not only by the progress of its own developments but also by the success of its partner, AstraZeneca, which is promoting a drug licensed from Innate. These royalties and milestone payments are key confirmation of the value of its platform.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Innate Pharma S.A. is a French biotech company developing immunotherapies for cancer treatment. Its stock price reflects both the potential of its scientific platform and the risks associated with clinical trials and partnerships with large pharmaceutical companies, which is typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Innate Pharma is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor expectations for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Innate Pharma S.A.
The value of Innate, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials of its immuno-oncology drugs, as well as revenue from partnerships with major pharmaceutical companies such as Sanofi and AstraZeneca.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in immuno-oncology. Its goal is to activate a patient's immune system to fight cancer. The dynamics of this cutting-edge sector reflect investors' faith in new treatment paradigms. The chart below illustrates the overall context against which Innate Pharma is developing its unique scientific platforms.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Innate Pharma S.A. is a French biotech company specializing in the development of immuno-oncology drugs targeting the innate immune system. The company's future depends on the success of its R&D and partnerships. The broader market chart serves only as a backdrop to demonstrate how scientific breakthroughs and clinical trial news have driven its stock price movement independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Innate Pharma S.A.
Innate Pharma S.A. is a French biotechnology company specializing in immuno-oncology. Its weekly stock price is driven by news about the clinical trials of its drugs and the success of its partners, such as AstraZeneca.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Innate Pharma is a biotech company specializing in immuno-oncology. Its value is determined by the potential of its drugs in development, not by current cash flows. Compare its weekly performance with the pharmaceutical sector to see how much clinical trial news influences its stock.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Innate Pharma is a biotech company whose shares are driven by news of clinical trials. It's a classic example of an asset that doesn't correlate with the market. The chart clearly demonstrates how much its performance is driven by scientific news rather than general economic trends.
Market capitalization of the company, segment and market as a whole
IPHA - Market capitalization of the company Innate Pharma S.A.
The market capitalization of Innate Pharma, a French biotech, reflects its focus on immuno-oncology. Its chart shows how investors value its scientific platform and partnerships with major pharmaceutical companies, such as AstraZeneca. The stock's performance is driven by the progress of its drugs in clinical trials.
IPHA - Share of the company's market capitalization Innate Pharma S.A. within the market segment - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in the development of immuno-oncology drugs targeting the innate immune system. Its market share reflects its scientific expertise. The graph shows its trajectory, filled with partnerships with major pharmaceutical companies and promising new cancer treatments.
Market capitalization of the market segment - Oncology immuno-therapy
The graph below shows the market capitalization of the immuno-oncology sector. Innate Pharma is a European pioneer in harnessing innate immunity to fight cancer. This market is full of ups and downs. Innate's story, with its partnerships with giants and its own developments, exemplifies the complexity and importance of finding new approaches to cancer treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
Innate Pharma is a French biotech company specializing in the development of immuno-oncology drugs that harness the innate immune system to fight cancer. Its market capitalization reflects its scientific approach. The chart below shows the importance of this area of research in oncology.
Book value capitalization of the company, segment and market as a whole
IPHA - Book value capitalization of the company Innate Pharma S.A.
Innate Pharma's book value is derived from its R&D platform, focused on immuno-oncology, and alliances with major pharmaceutical companies. This chart tells the story of a European biotech company whose asset value is derived from both its own developments and advance payments from partners like AstraZeneca.
IPHA - Share of the company's book capitalization Innate Pharma S.A. within the market segment - Oncology immuno-therapy
Innate Pharma is a pioneer in immuno-oncology. The chart shows its share of actual R&D assets. These are its research centers in France, where they are discovering new mechanisms of innate immunity to fight cancer.
Market segment balance sheet capitalization - Oncology immuno-therapy
Innate Pharma is a biotech company focused on R&D. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, clearly demonstrating its research-intensive, rather than manufacturing-driven, model.
Book value of all companies included in the broad market index - GURU.Markets
Innate Pharma is a biotechnology company specializing in immuno-oncology. Its assets include its scientific platform and development portfolio. Its stake in BCap_All is a material resource the company is investing in discovering new ways to "trigger" the human immune system against cancer cells.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Innate Pharma S.A.
Innate Pharma is a French biopharmaceutical company. Its asset premium reflects its scientific platform in the field of innate immunity and its partnerships with major pharmaceutical companies, such as AstraZeneca.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in immuno-oncology. Its value is determined by its pipeline. This metric represents a premium to its book value, reflecting investor expectations for the success of its innovative approaches to fighting cancer.
Market to book capitalization ratio for the market as a whole
Innate Pharma is a French biotech company specializing in immuno-oncology. Its market capitalization reflects the potential of its development pipeline. This chart demonstrates how biotech valuations depend on investor confidence in future scientific breakthroughs rather than on the current book value of assets.
Debts of the company, segment and market as a whole
IPHA - Company debts Innate Pharma S.A.
Innate Pharma, a French biotech focused on immuno-oncology, is using the capital to advance its development pipeline. Its debt strategy is aimed at funding its own clinical trials and supporting partnerships with major pharmaceutical companies, allowing it to diversify its risks.
Market segment debts - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in immuno-oncology. It develops drugs that harness the innate immune system to fight cancer. This chart shows the company's financial trajectory, including whether it relies on partnerships with major pharmaceutical companies and equity capital to fund its expensive research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Innate Pharma S.A.
Innate Pharma is a biotech company specializing in immuno-oncology. Partnerships with major pharma companies may reduce the need for debt, but R&D is still expensive. This chart shows the company's debt burden, which allows one to assess the company's financial strategy: whether it relies on upfront payments from partners or debt for financing.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in immuno-oncology. This chart reflects debt trends in the sector. It helps assess how the company, which has partnerships with major pharma giants, manages its capital and finances its development pipeline in one of the most promising areas of cancer treatment.
Debt to book value of all companies in the market
Innate Pharma S.A. is a French biotech company specializing in immuno-oncology. Its path to developing new drugs is long and requires significant investment in R&D. This chart of overall market leverage shows how the financial strategy of such companies deviates from the norm. They rely on investor capital rather than debt, making them vulnerable to stock market sentiment.
P/E of the company, segment and market as a whole
P/E - Innate Pharma S.A.
Innate Pharma is a French biotech company specializing in the development of immuno-oncology drugs. This chart shows how the market values its research pipeline and partnerships with major pharmaceutical companies. This value depends on the success of clinical trials and future royalties from drug sales.
P/E of the market segment - Oncology immuno-therapy
This chart shows the average valuation for biopharmaceutical companies, providing context for Innate Pharma. It reflects overall investor sentiment toward the sector. Comparisons with this valuation help us understand whether Innate Pharma's scientific platform in immuno-oncology and its partnerships with major pharma companies are viewed more or less optimistically by the market than their competitors.
P/E of the market as a whole
Innate Pharma is a French biotech company specializing in immuno-oncology. Its success depends on clinical development and partnerships with major pharmaceutical companies. This chart of overall risk appetite in the healthcare sector is an important indicator for Innate. During periods of optimism, investors are more willing to fund European biotechs and believe in their scientific platforms.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Innate Pharma S.A.
Innate Pharma is a French biotech company specializing in the development of immuno-oncology drugs targeting the innate immune system. This graph reflects expectations for its scientific platform. The assessment depends on the success of clinical trials, partnerships with major pharmaceutical companies, and the potential of its drugs in combination with other cancer therapies.
%20P%2FE%20Innate%20Pharma%20S.A.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Innate-Pharma-S.A.&v=1772614489754 "Chart of the company's future (projected) P/E Innate Pharma S.A.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Innate Pharma is a biotech company specializing in the development of cancer immunotherapies based on natural killer (NK) cells. This chart reflects investor expectations for the company's profitability relative to the sector. It provides insight into how the market views its scientific platform and partnerships with major pharmaceutical companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772614489850 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Innate Pharma is a French biotechnology company specializing in the development of immuno-oncology drugs. In line with overall market expectations, as reflected in this chart, Innate Pharma's business is driven by clinical trial results and partnerships with major pharmaceutical companies that help finance and commercialize their developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772614489925 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Innate Pharma S.A.
Innate Pharma is a French biotech company specializing in the development of immuno-oncology drugs that mobilize the body's own immune system to fight cancer. This chart shows the financial results of the company, which is working in one of the most promising areas of oncology treatment.
Profit of companies in the market segment - Oncology immuno-therapy
Innate Pharma is a biotech company specializing in the development of immuno-oncology drugs targeting the innate immune system. This chart shows profitability in the oncology sector. For IPHA, this is an indicator of the search for new approaches to fighting cancer. Their research is aimed at activating the body's first line of defense against tumors.
Overall market profit
Innate Pharma is a French biotechnology company specializing in the development of immuno-oncology drugs that mobilize the innate immune system to fight cancer. The company has partnerships with major pharmaceutical companies. Its success depends on research results. This graph does not reflect the specifics and risks of the biotechnology industry.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Innate Pharma S.A.
Innate Pharma is a French biotech company specializing in immuno-oncology. The profit forecast presented here depends on the success of its own developments and royalties received from partners such as AstraZeneca. Clinical trial data and regulatory decisions are key factors influencing expectations.
%20profit%20of%20the%20company%20Innate%20Pharma%20S.A.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Innate-Pharma-S.A.&v=1772614490181 "Graph of future (projected) profit of the company Innate Pharma S.A.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Innate Pharma specializes in immuno-oncology, developing drugs that target the innate immune system to fight cancer. The revenue forecast for this sector reflects expectations for new classes of drugs. This chart shows analysts' confidence in the commercial potential of next-generation immunotherapies following the success of checkpoint inhibitors.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772614490263 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Innate Pharma is a French biotech company specializing in immuno-oncology. Its success depends on partnerships with major pharmaceutical companies and clinical trial results. This graph, reflecting profit forecasts, influences big pharma's strategic budgets for the acquisition and licensing of promising developments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772614490408 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Innate Pharma S.A.
Innate Pharma is a French biotech company specializing in immuno-oncology. This chart shows how the market values its revenue, which consists of royalties and payments from partners such as AstraZeneca. This value depends on the success of joint developments and the progress of the company's own clinical programs.
P/S market segment - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in immuno-oncology. It develops drugs that harness the innate immune system to fight cancer. This chart shows the average revenue estimate for the sector, which helps understand how the market views Innate Pharma's scientific approach and clinical development pipeline.
P/S of the market as a whole
Innate Pharma is a French biotech company specializing in the development of immuno-oncology drugs that harness the innate immune system to fight cancer. Success depends on clinical trials. This chart provides a market-wide perspective on how investors view innovative approaches in oncology, given overall economic trends.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Innate Pharma S.A.
Innate Pharma is a French biotech company specializing in the development of immuno-oncology drugs that harness the innate immune system to fight cancer. This chart shows how investors estimate the company's future revenue based on the potential of its innovative approaches.
%20P%2FS%20Innate%20Pharma%20S.A.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Innate-Pharma-S.A.&v=1772614490703 "The graph of the company's future (projected) P/S Innate Pharma S.A.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Innate Pharma develops immuno-oncology drugs that harness the body's own immune system to fight cancer. This chart reflects the market assessment of its scientific platform and development pipeline in one of the most promising and competitive areas of modern oncology.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772614490742 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Innate Pharma is a French biotech company specializing in immuno-oncology. They develop drugs that help the immune system fight cancer. This market optimism graph is important for IPHA. It influences the willingness of large pharmaceutical companies to enter into partnerships and the overall influx of capital into the biotech sector to fund research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772614490787 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Innate Pharma S.A.
Innate Pharma is a French biotech company specializing in immuno-oncology. Although the company is in the clinical stage, it generates revenue from partnerships with major pharmaceutical companies, such as AstraZeneca. This chart reflects both research progress (milestone payments) and royalties from approved drugs.
Sales of companies in the market segment - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in immuno-oncology. They develop drugs that activate the innate immune system to fight cancer. Their business model is based on partnerships with major pharmaceutical companies, and their revenue structure reflects licensing fees and development milestones.
Overall market sales
Innate Pharma is a French biotechnology company specializing in the development of immunotherapies for the treatment of cancer. Its approach involves activating the innate immune system to fight tumors. This total revenue chart includes the healthcare sector, where IPHA works at the forefront of science to discover new ways to treat oncological diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Innate Pharma S.A.
Innate Pharma is a French biotech company specializing in the development of immuno-oncology drugs that target the innate immune system to fight cancer. This graph reflects analyst expectations for the success of its clinical programs, many of which are being conducted in partnership with major pharmaceutical companies.
%20sales%20of%20the%20company%20Innate%20Pharma%20S.A.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Innate-Pharma-S.A.&v=1772614490908 "Schedule of future (projected) sales of the company Innate Pharma S.A.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Innate Pharma is a biotech company specializing in the development of immuno-oncology drugs that harness the innate immune system to fight cancer. This chart shows forecasts for the entire cancer immunotherapy market. It reflects expectations for the development of new treatment approaches that could complement or improve existing methods.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772614490919 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Innate Pharma, a specialist in immuno-oncology, sees this chart as a reflection of the market's readiness for new cancer treatments. Rising overall economic forecasts provide stable funding for healthcare systems, allowing them to implement the advanced and expensive immunotherapeutic drugs Innate Pharma is developing and commercializing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772614491060 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Innate Pharma S.A.
Innate Pharma is a French biotech company specializing in immuno-oncology. Its financial performance reflects both revenue from partnerships with major pharmaceutical companies and high expenditures on its own clinical research. This chart illustrates the complex balance between current revenue and investments in its future cancer drug pipeline.
Market segment marginality - Oncology immuno-therapy
Innate Pharma specializes in developing immunotherapeutic drugs for the treatment of cancer using natural killer (NK) cells. This indicator reflects the commercial potential of its scientific platform. The company's success will be measured by the ability of its drugs to generate revenue above the industry average.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Innate Pharma S.A.
Innate Pharma is a French biotech company and a pioneer in the field of immuno-oncology. It specializes in developing drugs that stimulate the innate immune system to fight cancer. This graphic shows a team of researchers working on a new class of drugs that target NK (natural killer) cells to destroy tumors.
Share of the company's employees Innate Pharma S.A. within the market segment - Oncology immuno-therapy
Innate Pharma S.A. is a French biotech company specializing in immuno-oncology, specifically NK cells. Developing a new class of anti-cancer drugs requires an elite team of immunologist scientists. This chart highlights its scientific leadership, reflecting the unique talent it attracts in this cutting-edge field of cancer research.
Number of employees in the market segment - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in immuno-oncology. It develops drugs that activate the innate immune system to fight cancer. This graphic shows a team of immunologist scientists searching for new ways to spur a patient's body to attack tumor cells, opening new horizons in cancer treatment.
Number of employees in the market as a whole
Innate Pharma S.A. is a French biotechnology company specializing in immuno-oncology. The overall economic situation, as measured by employment trends, is important for their long-term growth. A strong economy supports public and private healthcare funding, enabling the implementation of cutting-edge treatments and stimulating investment in Innate Pharma's breakthrough research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Innate Pharma S.A. (IPHA)
Innate Pharma S.A. is a French biotech company specializing in immuno-oncology. This chart shows their research portfolio valuation. Their high market capitalization per employee suggests that investors see significant value in their drug discovery platform and partnerships with major pharmaceutical companies.
%20of%20the%20company%20Innate%20Pharma%20S.A.%20(IPHA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Innate-Pharma-S.A.-IPHA&v=1772614491637 "Chart of market capitalization per employee (in thousands of dollars) of the company Innate Pharma S.A. (IPHA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Innate Pharma S.A. is a French biotech company specializing in immuno-oncology. Its value is determined by its development portfolio and partnerships with major pharmaceutical companies. This chart shows the market's assessment of its scientific potential per employee, an important indicator in the high-tech biotech sector.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772614491661 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Innate Pharma is a French biotech company specializing in immuno-oncology, specifically NK cells. This metric reflects the value of its scientific platform. It shows how the market values its innovative approach to fighting cancer, where a single successful development can generate billions.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772614491686 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Innate Pharma S.A. (IPHA)
Innate Pharma is a French biotech focused on immuno-oncology. They develop antibodies that "teach" the immune system to attack cancer. This graph shows the company is in the R&D stage. Their business model often includes partnerships with big pharma, which allows them to fund research, but current profitability is negative.
%20Chart%20Innate%20Pharma%20S.A.%20(IPHA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Innate-Pharma-S.A.-IPHA&v=1772614491723 "Company Profit Per Employee (in thousands of dollars) Chart Innate Pharma S.A. (IPHA)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in immuno-oncology. They develop drugs that harness the innate immune system (NK cells) to fight cancer. This chart represents an industry benchmark. For Innate, which invests heavily in R&D, it serves as a benchmark for the profitability achieved in the pharmaceutical industry after commercializing breakthrough treatments.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772614491769 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Innate Pharma is a French biotech company specializing in immuno-oncology. They develop antibodies that help a patient's own immune system (NK cells) recognize and attack cancer. They are an R&D company that thrives on partnerships (for example, with AstraZeneca). This chart shows R&D expenditure per scientist and the effectiveness of these partnerships.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772614491830 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Innate Pharma S.A. (IPHA)
Innate Pharma is a French biotech company specializing in immuno-oncology. This chart illustrates its partnership-based model. A significant portion of its revenue per employee is generated through milestone payments and royalties from large pharmaceutical companies (such as AstraZeneca), with whom it co-develops drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Innate-Pharma-S.A.-IPHA&v=1772614491921 "Sales chart per company employee Innate Pharma S.A. (IPHA)")
Sales per employee in the market segment - Oncology immuno-therapy
Innate Pharma is a French biotech specializing in immuno-oncology (NK cells). They partner with major pharma (AstraZeneca). Their revenue comes primarily from royalties and partnerships, rather than direct sales. This chart shows how effective their R&D-focused model (scientists) is in generating this revenue per employee.
Sales per employee for the market as a whole
Innate Pharma is a French biotech company specializing in immuno-oncology. They develop drugs that harness the innate immune system (NK cells) to fight cancer. This chart shows the revenue generated by their research team, primarily from partnerships with Big Pharma and royalties.
Short shares by company, segment and market as a whole
Shares shorted by company Innate Pharma S.A. (IPHA)
Innate Pharma (IPHA) is a French biotech company specializing in the development of immuno-oncology drugs targeting NK (natural killer) cells. This chart shows short bets. A rise in shorts may reflect concerns about clinical trial results, heavy reliance on the partnership with AstraZeneca, or intense competition in the immuno-oncology field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Innate-Pharma-S.A.-IPHA&v=1772614492118 "Short Shares Chart for the Company Innate Pharma S.A. (IPHA)")
Shares shorted by market segment - Oncology immuno-therapy
Innate Pharma (IPHA) is a French biotech company specializing in immuno-oncology, specifically the development of drugs that activate NK cells. This chart illustrates the general skepticism in the biotech sector. It summarizes bearish bets, reflecting investor concerns about the risks of clinical trials.
Shares shorted by the overall market
Innate Pharma is a biotech company specializing in antibody-based cancer therapy. Being in the clinical stage, its lifeblood is R&D funding. The surge in overall market pessimism, visible in this chart, signals a "risk-off" environment in which raising capital is becoming difficult and expensive.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Innate Pharma S.A. (IPHA)
Innate Pharma (IPHA) is a French biotech company specializing in immuno-oncology. They develop drugs (targeting NK cells) that help the immune system fight cancer. This chart measures hype. It shows "overheated" (above 70) due to partnership news (e.g., with AstraZeneca) or "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Innate-Pharma-S.A.-IPHA&v=1772614492370 "RSI 14 indicator chart for the company's stock Innate Pharma S.A. (IPHA)")
RSI 14 Market Segment - Oncology immuno-therapy
Innate Pharma (IPHA) is a biotech company developing immuno-oncology drugs. They focus on innate immunity (NK cells) to attack cancer. This chart measures overall sentiment in the Immuno-Oncology sector. It helps distinguish IPHA's trial successes from general overheating or overselling across the biotech sector.
RSI 14 for the overall market
Innate Pharma (IPHA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IPHA (Innate Pharma S.A.)
Innate Pharma is a French biopharmaceutical company specializing in immuno-oncology. It develops drugs that activate natural killer (NK) cells to fight cancer. This chart shows the average analyst price target, based on its R&D and partnership with AstraZeneca.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IPHA-Innate-Pharma-S.A.&v=1772614492577 "A chart showing analyst consensus forecasts for the expected stock price. IPHA (Innate Pharma S.A.)")
The difference between the consensus estimate and the actual stock price IPHA (Innate Pharma S.A.)
Innate Pharma is a French biotech company focused on immuno-oncology. They specialize in NK (natural killer) cells, attempting to harness this part of the immune system to fight cancer. This chart shows how much analysts believe in their scientific platform and their partnerships with major pharma companies (AstraZeneca).
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IPHA-Innate-Pharma-S.A.&v=1772614492626 "A chart showing the difference between the consensus forecast and the actual stock price. IPHA (Innate Pharma S.A.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Innate Pharma (IPHA) is a French biotech company developing cancer immunotherapies. It focuses on NK cells (natural killer cells) as a new weapon against tumors. This chart shows analysts' overall expectations for the immunotherapy sector, reflecting their confidence in new R&D approaches.
Analysts' consensus forecast for the overall market share price
Innate Pharma is a French biotech company specializing in immuno-oncology, specifically developing drugs that activate NK (natural killer) cells to fight cancer. This chart shows the overall risk appetite. For Innate, as a clinical-stage company, overall market optimism is important for funding research and supporting partnerships with Big Pharma.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Innate Pharma S.A.
Innate Pharma is a French biotech specializing in innate immunity. They develop drugs (including a partnership with AstraZeneca) that activate NK (natural killer) cells to attack cancer. This chart is a summary of their R&D platform, reflecting their progress in clinical trials and their stable income from royalties and partnerships.
AKIMA Market Segment Index - Oncology immuno-therapy
Innate Pharma is a French biotech company specializing in immuno-oncology, specifically developing drugs that activate NK (natural killer) cells to fight cancer. This chart shows the average index for the immunotherapy sector. It allows one to assess how Innate Pharma's scientific platform compares to the industry average.
The AKIM Index for the overall market
Innate Pharma is a French biotech company specializing in immuno-oncology (NK cell targeting). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story, with its global partnerships (AstraZeneca, Sanofi), compares to overall economic trends.
